Thalidomide-mediated immunomodulation in a patient with IL-10RA deficiency-associated very early-onset inflammatory bowel disease
Frontiers in Immunology · 15.04.2026 · 17
DOI: 10.3389/fimmu.2026.1748151 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Immunology, online erschienen am 15.04.2026. Verfasst von Aiyan Ren und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Hauptthemen laut MEDLINE: Thalidomide, Inflammatory Bowel Diseases, Interleukin-10 Receptor alpha Subunit, Immunomodulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Very early-onset inflammatory bowel disease (VEO-IBD) is frequently triggered by monogenic defects in the pathways responsible for immune system regulation, including mutations in the interleukin-10 receptor alpha ( IL-10RA ) gene. Patients often show severe and refractory clinical manifestations. Thalidomide has shown immunomodulatory effects in pediatric IBD; however, its immunological effects in IL-10RA -associated VEO-IBD remain poorly defined.
Methods
A female patient aged 2 months diagnosed with VEO-IBD was enrolled in the study. Clinical data were gathered over time. Whole-exome sequencing was utilized to uncover pathogenic variants for genomic analysis. The expression of IL-10RA was assessed using Western blotting. Flow cytometry was performed both before and after treatment to evaluate the effect of the administration of thalidomide on the populations of T and B lymphocytes, alongside the immune activation levels.
Results
The patient experienced chronic diarrhea, failure to thrive, and recurrent infections. Genetic analysis revealed the presence of compound heterozygous mutations in the IL-10RA gene (c.301C>T and c.537G>A). Western blotting analysis revealed a reduction in the levels of IL-10RA protein expression. Immunophenotyping showed an increase in the percentages of γδ T cells, Th17 cells, transitional B cells, and activated CD8 + T cells before treatment. After thalidomide therapy, the symptoms of diarrhea resolved, the growth parameters improved, the proportions of γδ T cells and transitional B cells decreased, and the inflammatory markers returned to normal levels.
Discussion
This study confirms the immune dysregulation caused by IL-10RA gene mutation in VEO-IBD and demonstrates that thalidomide treatment can improve clinical symptoms and modulate specific lymphocyte subsets. The immune mechanisms behind the response to thalidomide in IL-10RA -associated VEO-IBD should be further explored.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- Guizhou Children's Hospital, Zunyi, China.
Zitieren
APA
Ren, A., Zeng, Q., Zhang, B., Chuan, X., Wu, Y., Wang, M., Ren, H., Chen, Y., Huang, P., & Du, Z. (2026). Thalidomide-mediated immunomodulation in a patient with IL-10RA deficiency-associated very early-onset inflammatory bowel disease. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1748151
Vancouver
Ren A, Zeng Q, Zhang B, Chuan X, Wu Y, Wang M, et al. Thalidomide-mediated immunomodulation in a patient with IL-10RA deficiency-associated very early-onset inflammatory bowel disease. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1748151
BibTeX
@article{Ren2026,
author = {Ren, Aiyan and Zeng, Qian and Zhang, Bin and Chuan, Xue and Wu, Yalin and Wang, Meiting and Ren, Huan and Chen, Yan and Huang, Pei and Du, Zuochen},
title = {Thalidomide-mediated immunomodulation in a patient with IL-10RA deficiency-associated very early-onset inflammatory bowel disease},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1748151}
}
EUVIMED